Indivior Pharmaceuticals, Inc 6-K, filed Nov 15, 2024
Indivior Pharmaceuticals, Inc. (INDV)
6-K
2024-11-15
For: 2024-11-15
View Original
Added on
April 10, 2026
About this 6-K
Indivior Pharmaceuticals, Inc filed this 6-K on November 15, 2024.
|
|
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
________________________
Washington, D.C. 20549
_____________________
FORM 6-K
_____________________
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of November 2024
Commission File Number: 001-37835
________________________________________
Indivior PLC
________________________________________
10710 Midlothian Turnpike, Suite 125
North Chesterfield, Virginia 23235
(Address of principal executive office)
_______________________________
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F
Form
20-F ☒ Form 40-F ☐
|
|
EXHIBIT INDEX
|
Exhibit
No.
|
Description
of Exhibit
|
|
99.1
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
Indivior PLC
|
|
Date: November 15,
2024
|
/s/
Kathryn Hudson
|
|
|
Name:
Kathryn Hudson
|
|
|
Title:
Company Secretary
|
Exhibit
99.1
INDIVIOR PLC (the 'Company')
DIRECTOR DECLARATION
Richmond, VA, and Slough, UK, November 15, 2024 -
The Board of Directors of Indivior
PLC (Nasdaq/LSE:
INDV) have agreed that Jerome Lande will continue to serve as a
Non-Executive Director until December 31, 2024, whereupon he will
step down from the Board.
The Company's relationship agreement with Scopia
Capital Management LP ("Scopia"), otherwise due to expire on
December 31, 2024, has terminated in accordance with its terms
because the aggregate of Scopia's and its affiliates' interests in
the issued share capital of the Company has reduced below the
threshold for automatic termination. Notwithstanding that the
threshold for automatic termination has been crossed, the Board and
Scopia have agreed that Jerome Lande will continue to serve as a
Non-Executive Director until December 31, 2024.
The Board would like
to express its sincere thanks to Jerome for his significant
contribution to Indivior since joining the Board in
2021.
About Indivior
Indivior is a global pharmaceutical company working to help change
patients' lives by developing medicines to treat substance use
disorders (SUD), overdose and serious mental illnesses. Our vision
is that all patients around the world will have access to
evidence-based treatment for the chronic conditions and
co-occurring disorders of SUD. Indivior is dedicated to
transforming SUD from a global human crisis to a recognized and
treated chronic disease. Building on its global portfolio of OUD
treatments, Indivior has a pipeline of product candidates designed
to both expand on its heritage in this category and potentially
address other chronic conditions and co-occurring disorders of SUD.
Headquartered in the United States in Richmond, VA, Indivior
employs over 1,000 individuals globally and its portfolio of
products is available in over 30 countries worldwide.
Visit www.indivior.com to
learn more. Connect with Indivior on LinkedIn by
visiting www.linkedin.com/company/indivior.
For Further Information
|
Investor Enquiries
|
Jason Thompson
|
VP,
Investor Relations
Indivior
PLC
|
+1
804 402 7123
jason.thompson@indivior.com
|
|
|
Tim Owens
|
Director,
Investor Relations Indivior PLC
|
+1
804 263 3978
timothy.owens@indivior.com
|
|
Media Enquiries
|
Jonathan Sibun
|
Teneo
U.S.
Media Inquiries
|
+44
(0)20 7353 4200
+1
804 594 0836
Indiviormediacontacts@indivior.com
|